All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
During the 48th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), the Lymphoma Hub was pleased to speak with Miguel-Angel Perales, Memorial Sloan Kettering Cancer Center, New York, US. We asked, Does prior use of checkpoint inhibitors impact allogeneic stem cell transplantation outcomes for patients with Hodgkin lymphoma?
Does prior use of checkpoint inhibitors impact allo-SCT outcomes for patients with Hodgkin lymphoma?
Perales begins by discussing the new therapies that have become available in the past decade to treat Hodgkin lymphoma, such as rituximab and checkpoint inhibitors. This is followed by a summary of the joint study between the Center for International Blood and Marrow Transplant Research (CIBMTR) and EBMT, which aimed to investigate if receiving a checkpoint inhibitor prior to allogeneic transplant impacted progression-free and overall survival in patients with Hodgkin lymphoma. Perales finishes by discussing the importance of having a curative approach available.
What role is there for allogeneic SCT in the treatment of Hodgkin lymphoma?
During The 6th International Congress on Controversies in Stem Cell Transplantation and Cellular Therapies (COSTEM 2021), the Lymphoma Hub was pleased to speak with Anna...
Progress in immunotherapy for hematologic malignancies
Immunotherapy has long been part of the armamentarium of therapies for hematologic malignancies. One of the first applications of immunotherapy was the use of allogeneic stem cell transplantation...
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox